866-997-4948(US-Canada Toll Free)

Januvia (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 46 Pages


GlobalData has released its new report, Januvia (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Januvia (sitagliptin) was approved in 2006, and was the first new oral medication for diabetes in more than a decade, and the first medicine approved by the FDA to inhibit the enzyme DPP-4. Januvia is a once-daily oral tablet, developed by Merck, that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Januvia including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Januvia for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Januvia performance
  • Obtain sales forecast for Januvia from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Januvia (sitagliptin) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 32

7 Appendix 34
7.1 Bibliography 34
7.2 Abbreviations 37
7.3 Methodology 38
7.4 Forecasting Methodology 38
7.4.1 Diagnosed Type 2 Patients 38
7.4.2 Percent Drug-Treated Patients 39
7.4.3 Drugs Included in Each Therapeutic Class 39
7.4.4 Launch and Patent Expiry Dates 39
7.4.5 General Pricing Assumptions 40
7.4.6 Individual Drug Assumptions 41
7.4.7 Generic Erosion 41
7.5 Physicians and Specialists Included in this Study 41
7.6 About the Authors 43
7.6.1 Analyst II - CVMD 43
7.6.2 Therapy Director - CVMD and Infectious Disease 43
7.6.3 Global Head of Healthcare 44
7.7 About GlobalData 45
7.8 Disclaimer 45

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile - Januvia 29
Table 7: Januvia SWOT Analysis, 2012 31
Table 8: Global Sales Forecasts ($m) for Januvia and Janumet, 2012-2022 33
Table 9: Key Launch Dates 39
Table 10: Key Patent Expiry Dates 39
Table 11: Number of High-Prescribing Physicians Surveyed 42

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *